ImmunityBio Inc. (IBRX)
ImmunityBio Statistics
Share Statistics
ImmunityBio has 853.44M shares outstanding. The number of shares has increased by 8.34% in one year.
Shares Outstanding | 853.44M |
Shares Change (YoY) | 8.34% |
Shares Change (QoQ) | 4.83% |
Owned by Institutions (%) | 11.87% |
Shares Floating | 88.78M |
Failed to Deliver (FTD) Shares | 73.57K |
FTD / Avg. Volume | 1.2% |
Short Selling Information
The latest short interest is 54.54M, so 7.47% of the outstanding shares have been sold short.
Short Interest | 54.54M |
Short % of Shares Out | 7.47% |
Short % of Float | 71.83% |
Short Ratio (days to cover) | 9.56 |
Valuation Ratios
The PE ratio is -4.32 and the forward PE ratio is -7.33. ImmunityBio's PEG ratio is 0.09.
PE Ratio | -4.32 |
Forward PE | -7.33 |
PS Ratio | 121.07 |
Forward PS | 1.1 |
PB Ratio | -3.66 |
P/FCF Ratio | -4.48 |
PEG Ratio | 0.09 |
Enterprise Valuation
ImmunityBio Inc. has an Enterprise Value (EV) of 3.17B.
EV / Earnings | -7.67 |
EV / Sales | 215.09 |
EV / EBITDA | -11.99 |
EV / EBIT | -9.21 |
EV / FCF | -7.97 |
Financial Position
The company has a current ratio of 3.36, with a Debt / Equity ratio of -0.09.
Current Ratio | 3.36 |
Quick Ratio | 3.21 |
Debt / Equity | -0.09 |
Total Debt / Capitalization | -9.49 |
Cash Flow / Debt | -9.25 |
Interest Coverage | -2.61 |
Financial Efficiency
Return on equity (ROE) is 0.85% and return on capital (ROIC) is 77.37%.
Return on Equity (ROE) | 0.85% |
Return on Assets (ROA) | -1.08% |
Return on Capital (ROIC) | 77.37% |
Revenue Per Employee | $21,683.82 |
Profits Per Employee | $-608,182.35 |
Employee Count | 680 |
Asset Turnover | 0.04 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -41.9% in the last 52 weeks. The beta is -0.18, so ImmunityBio's price volatility has been lower than the market average.
Beta | -0.18 |
52-Week Price Change | -41.9% |
50-Day Moving Average | 3.12 |
200-Day Moving Average | 4.13 |
Relative Strength Index (RSI) | 54.11 |
Average Volume (20 Days) | 6.12M |
Income Statement
In the last 12 months, ImmunityBio had revenue of 14.74M and earned -413.56M in profits. Earnings per share was -0.59.
Revenue | 14.74M |
Gross Profit | 14.74M |
Operating Income | -344.18M |
Net Income | -413.56M |
EBITDA | -264.43M |
EBIT | -344.18M |
Earnings Per Share (EPS) | -0.59 |
Balance Sheet
The company has 143.43M in cash and 42.29M in debt, giving a net cash position of 101.14M.
Cash & Cash Equivalents | 143.43M |
Total Debt | 42.29M |
Net Cash | 101.14M |
Retained Earnings | -3.38B |
Total Assets | 382.93M |
Working Capital | 94.86M |
Cash Flow
In the last 12 months, operating cash flow was -391.24M and capital expenditures -6.89M, giving a free cash flow of -398.12M.
Operating Cash Flow | -391.24M |
Capital Expenditures | -6.89M |
Free Cash Flow | -398.12M |
FCF Per Share | -0.57 |
Margins
Gross margin is 100%, with operating and profit margins of -2.33K% and -2.8K%.
Gross Margin | 100% |
Operating Margin | -2.33K% |
Pretax Margin | -2.8K% |
Profit Margin | -2.8K% |
EBITDA Margin | -1.79K% |
EBIT Margin | -2.33K% |
FCF Margin | -2.7K% |
Dividends & Yields
IBRX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -18.91% |
FCF Yield | -14.93% |
Analyst Forecast
The average price target for IBRX is $8, which is 156.4% higher than the current price. The consensus rating is "Buy".
Price Target | $8 |
Price Target Difference | 156.4% |
Analyst Consensus | Buy |
Analyst Count | 5 |
Scores
Altman Z-Score | -12.46 |
Piotroski F-Score | 4 |